Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

Similar articles for PubMed (Select 22941182)

2.

Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus.

Albano L, Berthoux F, Moal MC, Rostaing L, Legendre C, Genin R, Toupance O, Moulin B, Merville P, Rerolle JP, Bayle F, Westeel PF, Glotz D, Kossari N, Lefrançois N, Charpentier B, Blanc AS, Di Giambattista F, Dantal J; RAD A2420 Study Group.

Transplantation. 2009 Jul 15;88(1):69-76. doi: 10.1097/TP.0b013e3181aa7d87.

PMID:
19584683
3.

A systematic approach to minimizing wound problems for de novo sirolimus-treated kidney transplant recipients.

Tiong HY, Flechner SM, Zhou L, Wee A, Mastroianni B, Savas K, Goldfarb D, Derweesh I, Modlin C.

Transplantation. 2009 Jan 27;87(2):296-302. doi: 10.1097/TP.0b013e318192dd56.

PMID:
19155988
4.

Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients.

Nashan B, Gaston R, Emery V, Säemann MD, Mueller NJ, Couzi L, Dantal J, Shihab F, Mulgaonkar S, Seun Kim Y, Brennan DC.

Transplantation. 2012 Jun 15;93(11):1075-85. doi: 10.1097/TP.0b013e31824810e6. Review.

PMID:
22683823
5.

Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials.

Pengel LH, Liu LQ, Morris PJ.

Transpl Int. 2011 Dec;24(12):1216-30. doi: 10.1111/j.1432-2277.2011.01357.x. Epub 2011 Sep 29. Review.

PMID:
21955006
6.

mTOR inhibitors in pediatric kidney transplantation.

Pape L, Ahlenstiel T.

Pediatr Nephrol. 2014 Jul;29(7):1119-29. doi: 10.1007/s00467-013-2505-9. Epub 2013 Jun 7. Review.

PMID:
23740036
7.

Mammalian target of rapamycin (mTOR) inhibitors slow skin carcinogenesis, but impair wound healing.

Feldmeyer L, Hofbauer GF, Böni T, French LE, Hafner J.

Br J Dermatol. 2012 Feb;166(2):422-4. doi: 10.1111/j.1365-2133.2011.10591.x. Epub 2011 Dec 5.

PMID:
21895616
8.

Impact of de novo everolimus-based immunosuppression on incisional complications in heart transplantation.

Zuckermann A, Arizon JM, Dong G, Eisen HJ, Kobashigawa J, Lehmkuhl H, Ross H, Pelligrini C, Wang SS, Barten MJ.

Transplantation. 2011 Sep 15;92(5):594-600. doi: 10.1097/TP.0b013e3182279133.

PMID:
21862955
9.

mTOR inhibitor-associated proteinuria in kidney transplant recipients.

Diekmann F, Andrés A, Oppenheimer F.

Transplant Rev (Orlando). 2012 Jan;26(1):27-9. doi: 10.1016/j.trre.2011.10.003. Review.

PMID:
22137729
10.

Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.

Sánchez-Fructuoso AI, Ruiz JC, Pérez-Flores I, Gómez Alamillo C, Calvo Romero N, Arias M.

Transplant Proc. 2010 Oct;42(8):3050-2. doi: 10.1016/j.transproceed.2010.07.083.

PMID:
20970607
11.

Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients.

Knight RJ, Villa M, Laskey R, Benavides C, Schoenberg L, Welsh M, Kerman RH, Podder H, Van Buren CT, Katz SM, Kahan BD.

Clin Transplant. 2007 Jul-Aug;21(4):460-5.

PMID:
17645704
12.

Therapy of sclerodermatous chronic graft-versus-host disease with mammalian target of rapamycin inhibitors.

Jedlickova Z, Burlakova I, Bug G, Baurmann H, Schwerdtfeger R, Schleuning M.

Biol Blood Marrow Transplant. 2011 May;17(5):657-63. doi: 10.1016/j.bbmt.2010.07.025. Epub 2010 Aug 7.

PMID:
20696263
13.

Everolimus: efficacy and safety in cardiac transplantation.

Schaffer SA, Ross HJ.

Expert Opin Drug Saf. 2010 Sep;9(5):843-54. doi: 10.1517/14740338.2010.511611. Review.

PMID:
20701555
14.

Treatment with everolimus is associated with a procoagulant state.

Baas MC, Gerdes VE, Ten Berge IJ, Heutinck KM, Florquin S, Meijers JC, Bemelman FJ.

Thromb Res. 2013 Aug;132(2):307-11. doi: 10.1016/j.thromres.2013.07.004. Epub 2013 Jul 29.

PMID:
23906938
15.

Risk evaluation and mitigation strategies: a focus on the mammalian target of rapamycin inhibitors.

Gabardi S.

Prog Transplant. 2013 Mar;23(1):55-7. doi: 10.7182/pit2013235.

PMID:
23448821
16.

Sirolimus, the first mTOR inhibitor.

Sánchez-Plumed JA, González Molina M, Alonso A, Arias M.

Nefrologia. 2006;26 Suppl 2:21-32. Review. English, Spanish. No abstract available.

PMID:
17937632
17.
18.

Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial.

Dantal J, Berthoux F, Moal MC, Rostaing L, Legendre C, Genin R, Toupance O, Moulin B, Merville P, Rerolle JP, Bayle F, Westeel PF, Glotz D, Kossari N, Lefrançois N, Charpentier B, Quéré S, Di Giambattista F, Cassuto E; RAD A2420 Study Group.

Transpl Int. 2010 Nov;23(11):1084-93. doi: 10.1111/j.1432-2277.2010.01094.x. Epub 2010 Aug 19. Erratum in: Transpl Int. 2012 Jan;25(1):138.

PMID:
20500493
19.

Can immunosuppressive strategies be used to reduce cancer risk in renal transplant patients?

Geissler EK.

Transplant Proc. 2010 Nov;42(9 Suppl):S32-5. doi: 10.1016/j.transproceed.2010.07.004. Review.

PMID:
21095449
20.

Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients.

Kuppahally S, Al-Khaldi A, Weisshaar D, Valantine HA, Oyer P, Robbins RC, Hunt SA.

Am J Transplant. 2006 May;6(5 Pt 1):986-92.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk